These results were also in line with previous reports that circulating naïve PD-1+ PBMC, CD4+PD-1+ T cells, and the balance between circulating CD8+PD-1+ and CD4+PD-1+ were negatively correlated with survival or benefit from immune checkpoint blockers in advanced NSCLC (48–50). The gene discussed is CD4; the disease is non-small cell lung carcinoma.